Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 50Melanoma 23Neoplasms 19Neoplasm Metastasis 19Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 13Skin Neoplasms 12Recurrence 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 9Prostatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma, Basal Cell 8Breast Neoplasms 8Urinary Bladder Neoplasms 7Carcinoma, Merkel Cell 7Triple Negative Breast Neoplasms 6Colonic Neoplasms 6Carcinoma 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Glioblastoma 5Stomach Neoplasms 4Multiple Myeloma 4Mouth Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

cemiplimab 3Transdermal Patch 1Sirolimus 1Prednisone 1Everolimus 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Cutaneous Squamous Cell Carcinoma × cemiplimab × Clear all
NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
415 enrolled 1 FDA
Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT04154943 2025-12-23

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 2 Completed
79 enrolled 16 charts
Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT04339062 2025-04-23

CONTRAC

Dana-Farber Cancer Institute

Phase 1/2 Completed
12 enrolled 13 charts
Dermatologic

Cutaneous Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡